Your browser doesn't support javascript.
loading
Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
Klonoff, David C; Kim, Sun H; Galindo, Rodolfo J; Joseph, Jeffery I; Garrett, Valerie; Gombar, Saurabh; Aaron, Rachel E; Tian, Tiffany; Kerr, David.
Afiliación
  • Klonoff DC; Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, California, USA.
  • Kim SH; Department of Medicine - Endocrinology, Gerontology, and Metabolism, Stanford University School of Medicine, Stanford, California, USA.
  • Galindo RJ; Division of Endocrinology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • Joseph JI; Department of Anesthesiology, The Jefferson Artificial Pancreas Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Garrett V; Atropos Health, Palo Alto, California, USA.
  • Gombar S; Atropos Health, Palo Alto, California, USA.
  • Aaron RE; Diabetes Technology Society, Burlingame, California, USA.
  • Tian T; Diabetes Technology Society, Burlingame, California, USA.
  • Kerr D; Center for Health Systems Research, Sutter Health, Walnut Creek, California, USA.
Diabetes Obes Metab ; 26(8): 3128-3136, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38742898
ABSTRACT

AIM:

To assess whether adults with diabetes on oral hypoglycaemic agents undergoing general endotracheal anaesthesia during nine common surgical procedures who are glucagon-like peptide-1 receptor agonist (GLP1-RA) users, compared with non-users, are at increased risk of six peri- and post-procedure complications. MATERIALS AND

METHODS:

A retrospective observational cohort analysis of over 130 million deidentified US adults with diabetes (defined as being on oral hypoglycaemic agents) from a nationally representative electronic health dataset between 1 January 2015 and 1 April 2023 was analysed. Cohorts were matched by high-dimensionality propensity scoring. We compared the odds of six peri- and postoperative complications in GLP1-RA users and non-users. A sensitivity analysis compared these odds in GLP1-RA users to non-users with diabetes and obesity. We measured the odds of (a) a composite outcome of postoperative decelerated gastric emptying, including antiemetic use, ileus within 7 days post-procedure, gastroparesis diagnosis, gastric emptying study; (b) postoperative aspiration or pneumonitis; (c) severe respiratory failure; (d) postoperative hypoglycaemia; (e) inpatient mortality; and (f) 30-day mortality.

RESULTS:

Among 13 361 adults with diabetes, 16.5% were treated with a GLP1-RA. In the high-dimensionality propensity score-matched cohort, GLP1-RA users had a lower risk of peri- and postoperative complications for decelerated gastric emptying and antiemetic use compared with non-users. The risk of ileus within 7 days, aspiration/pneumonitis, hypoglycaemia and 30-day mortality were not different. A sensitivity analysis showed similar findings in patients with diabetes and obesity.

CONCLUSION:

No increased risk of peri- and postoperative complications in GLP1-RA users undergoing surgery with general endotracheal anaesthesia was identified.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Complicaciones Posoperatorias / Receptor del Péptido 1 Similar al Glucagón / Hipoglucemiantes Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Complicaciones Posoperatorias / Receptor del Péptido 1 Similar al Glucagón / Hipoglucemiantes Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos